CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I, Dose-Escalation Trial of Anti-GARP Chimeric Antigen Receptor-T Cell Therapy in Patients With Recurrent High-Grade Glioma Treated at a Single Medical Center

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06964737
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:29:01.069683+00:00
Published At: 2025-10-29T00:00:00+00:00
Record Updated At: 2025-10-29
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Recurrent Malignant Glioma", "Recurrent WHO Grade 3 Glioma", "Recurrent WHO Grade 4 Glioma", "WHO Grade 2 Glioma", "WHO Grade 3 Glioma", "WHO Grade 4 Glioma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-10-29"
protocolSection.identificationModule.nctId: "NCT06964737"
protocolSection.identificationModule.officialTitle: "A Phase I, Dose-Escalation Trial of Anti-GARP Chimeric Antigen Receptor-T Cell Therapy in Patients With Recurrent High-Grade Glioma Treated at a Single Medical Center"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.